Libida vs Vyleesi: What Each Costs Per Dose, and Which One Is Approved for a Woman Your Age

The HRT Index Editorial TeamIndependent women's health research

Last reviewed:August 11, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 11, 2026 · Last verified: August 11, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Before choosing Libida or Vyleesi

Premenopausal and eligible for Vyleesi? It is the better-documented option and may cost $0. If you will not inject, Libida has a route advantage with more unknowns. Compare the trade-offs before paying.

Find My HRT Path

We earn nothing from links to Libida or Vyleesi in this comparison. The HRT Index has an active affiliate relationship with Inner Balance for some site content, but the Libida links on this page are unpaid. We are not paid by Cosette Pharmaceuticals. We may earn a commission from certain labeled telehealth links later in the article.

Libida vs Vyleesi comes down to one hard line: only Vyleesi is FDA-approved, and only for premenopausal women with acquired, generalized HSDD. If you fit that label, Vyleesi is the better-documented choice and may cost $0 with eligible commercial coverage or $99 for four doses without coverage. After menopause, neither product is FDA-approved for you.

That last sentence is the part most pages leave out. And the $99 is the part almost every comparison leaves out.

Here is what changes the answer: your menopause status, blood pressure and heart history, whether pain or dryness is the real problem, what other medicines you take, whether you will use an injection, and whether you qualify for the manufacturer’s access program.

Looking for general information about low libido rather than these two specific products? Start with low libido and menopause.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Who is Libida best for, who is Vyleesi best for, and who should choose neither?

Libida is the route-first option for someone who will not inject and accepts a compounded, non-refundable product. Vyleesi is the evidence-first option for a premenopausal woman who meets its labeled HSDD criteria and has no contraindication. Neither should be the starting point when pain, bleeding, cardiovascular risk, pregnancy, medication effects, or another untreated cause is driving the problem.

Libida is worth a look if…

You will not inject yourself, full stop, and that is the thing standing between you and trying an on-demand prescription.
You want something used around anticipated intimacy, not a daily pill.
You specifically want to avoid estrogen, progesterone, and testosterone. Libida does contain oxytocin, which is itself a hormone.
You understand that Libida is compounded, so the FDA has not reviewed the finished tablet for safety, effectiveness, or quality before marketing.
You can absorb a non-refundable charge if it does nothing for you.

Vyleesi is probably your answer if…

You have not gone through menopause.
A clinician is evaluating acquired, generalized HSDD.
You want a defined 1.75 mg dose, an FDA-reviewed label, and product-specific trial data.
You can use a subcutaneous autoinjector.
You can accept a real first-dose nausea risk and make a plan with your prescriber.
You may qualify for $0 commercial-insurance pricing, or the $99 four-dose cash pathway fits your budget.

Neither is your starting point if…

You are past menopause and nobody has looked at why your desire changed.
Sex hurts, or dryness makes you avoid it. That is a different problem with a different treatment path.
You have new bleeding after menopause.
You have uncontrolled high blood pressure or known cardiovascular disease. Those are Vyleesi contraindications, not minor cautions.
A new medication, depression, severe stress, trauma, coercion, or a major relationship change lines up with when your desire changed.

A licensed clinician decides whether any prescription is right for you. This page shows the differences that should shape that conversation. It does not diagnose HSDD or promise a prescription.

Libida vs Vyleesi at a glance

Vyleesi has the FDA-reviewed dose, label, trials, and published adverse-event rates. Libida has the needle-free route and a lower published unit price on larger plans, but it is compounded, non-refundable, and supported by less product-specific public evidence. The table shows the decision facts before the deeper proof.

Decision fact	Vyleesi	Libida
FDA-approved?	Yes. NDA 210557; approved in 2019	No. Compounded finished product
Approved for whom?	Premenopausal women with acquired, generalized HSDD	No FDA-approved use; Inner Balance markets it across pre-, peri-, post-, and surgical menopause
How you take it	1.75 mg subcutaneous autoinjector	Compounded tablet dissolved under the tongue
Published ingredients and strength	Bremelanotide 1.75 mg/0.3 mL on the FDA label	Inner Balance’s help-center material publishes bremelanotide 1 mg plus oxytocin 20 IU; confirm the dispensed label because the sales page does not display the strengths
Current access price	Most eligible commercially insured patients may pay $0; $99 for a four-dose box when coverage is absent or denied, subject to program terms	Published charges range from $199 to $299; calculated price is about $9.97–$24.90 per tablet, with a conflict on the 20-tablet plan
Trials on this exact product	Two Phase 3 trials; 1,247 women	No published controlled trial of the exact finished formulation located
Refundable?	Pharmacy and program terms apply	No. Inner Balance’s refund policy specifically excludes Libida
Most important catch	Nausea affected 40% across trials; contraindicated with uncontrolled hypertension or known cardiovascular disease	Product-specific dose-response, absorption, adverse-event rates, pharmacy identity, and state availability are not fully public

Last verified August 2026. Every figure below is linked to a dated provider, manufacturer, FDA, label, or peer-reviewed source.

What we actually verified

This page follows The HRT Index Verification Standard. We checked the same five pillars in the same order: clinical legitimacy, care quality, medication fit, price transparency, access. We do not convert those pillars into a numeric score.

We read firsthand: Vyleesi’s current FDA label; Cosette’s current patient and access program pages; Inner Balance’s Libida product page, pricing guide, refund policy, HSA/FSA page, terms, and related comparison articles; the FDA’s compounding guidance; the RECONNECT trial publication; the current Addyi label; the global testosterone consensus statement; and the randomized oxytocin studies discussed below.

We calculated ourselves: every per-tablet, per-dose, billing-cycle, unused-tablet, and use-rate figure on this page. Inner Balance and Cosette publish the inputs. The HRT Index did the arithmetic and shows the formulas.

We could not verify: a published controlled trial of Libida’s exact formulation; public pharmacokinetic or absorption data for the tablet; the legal name of the pharmacy that fills it; a current Libida-specific state map; a public lot-level certificate of analysis; or a large independent Libida review pool. We have not used either product.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

Are Libida and Vyleesi the same medication?

No. Both products are described as containing bremelanotide, but they are different finished prescription products. Vyleesi is an FDA-approved 1.75 mg injection. Libida is a compounded sublingual tablet that Inner Balance describes as combining bremelanotide with oxytocin. Their route, formulation, evidence, labeling, quality controls, and regulatory oversight are not interchangeable.

Here is the thing that trips almost everyone up, and it is worth slowing down for.

When you compare two medicines, the ingredient name is one row in the table. It is not the verdict. What gets studied, approved, and labeled is the finished product: this ingredient, at this strength, in this dosage form, taken by this route, tested in these people, with these outcomes and these adverse events.

Change the route and you have changed the product. Add a second ingredient and you have changed it again.

Inner Balance’s own comparison copy uses the phrase “Same active ingredient. Totally different experience.” That is the company’s wording, not ours. In 2026, the FDA specifically warned telehealth companies not to promote compounded drugs as generics, as the same as an FDA-approved drug, as having the same active ingredient, or as clinically proven equivalents. Read the FDA’s telehealth-compounding warning.

What is fair to say: Inner Balance says Libida contains bremelanotide and oxytocin. Vyleesi contains bremelanotide. Vyleesi has been reviewed and approved by the FDA; Libida has not.

What is not fair to say: that Libida is “generic Vyleesi,” “oral Vyleesi,” a “needle-free version of Vyleesi,” or medically equivalent to it.

What “compounded” actually means

A compounded drug is prepared for a patient under a prescription through a pharmacy or another lawful compounding pathway. Compounding can meet a real clinical need. It does not create FDA approval.

The FDA is explicit: compounded drugs are not FDA-approved, and the agency does not review their safety, effectiveness, or quality before marketing in the way it reviews approved drugs. The FDA also says a compounded drug may be appropriate when a patient’s medical needs cannot be met by an available approved drug. Read the FDA’s compounded-drug risk explanation.

That is not a moral judgment about Libida. It is the regulatory category. A good prescriber should be able to explain why a compounded route is being chosen for you and what quality controls apply to the pharmacy filling it.

Credit where it is due

Inner Balance does disclose that Libida is compounded. Its public product page gives a clear use instruction: dissolve one tablet under the tongue 30–60 minutes before intimacy and do not take more than one tablet in 72 hours. Its strongest honest advantage is also obvious: it does not require an injection.

The company’s help-center material has published a formula of bremelanotide 1 mg plus oxytocin 20 IU. That is better than leaving the strengths completely undisclosed. The problem is placement: those numbers are not displayed on the public sales page beside the price, safety claims, or checkout path. Confirm that the strength on the dispensed prescription label matches before you take it.

We would rather tell you that than pretend this is a simple villain story. It is not.

→ Read our full Libida investigation — what is in it, what it costs, what the evidence can support, and what to verify before you pay. No commission. No affiliate link.

Libida vs Vyleesi: the full comparison

Vyleesi is a defined 1.75 mg bremelanotide injection approved for premenopausal women with acquired, generalized HSDD, with public trial data and adverse-event rates. Libida is a compounded sublingual bremelanotide-plus-oxytocin tablet with no published controlled trial or pharmacokinetic study of the exact finished formulation located in this review.

Every row is either provider-published, traced to a primary source, or explicitly labeled as The HRT Index’s calculation.

Decision point	Vyleesi	Libida
Regulatory status	FDA-approved prescription drug	Compounded prescription product; not FDA-approved
Named ingredients	Bremelanotide	Inner Balance says bremelanotide plus oxytocin; sales page also references flavoring/excipients but does not publish a complete dispensed-label copy
Published strength	1.75 mg/0.3 mL on the FDA label	Provider help-center material: bremelanotide 1 mg plus oxytocin 20 IU; confirm the dispensed label
Route	Subcutaneous autoinjector	Sublingual tablet
Product-specific absorption data	Yes; injection pharmacokinetics are in the label	No public pharmacokinetic or bioavailability study located for the exact tablet
When to take it	At least 45 minutes before anticipated activity	Product page says 30–60 minutes before intimacy; several Inner Balance articles say 45–60 minutes
How long it lasts	FDA label says duration of efficacy after each dose is unknown	Product page says up to 72 hours; other Inner Balance material describes 4–12 hours for most women, some 24–72 hours, and another page says up to 24 hours
Maximum use	No more than one dose in 24 hours; more than eight doses per month is not recommended	Product page: no more than one tablet in 72 hours. Inner Balance’s help center also says not to exceed 10 doses per month; follow the prescriber’s instructions
Who it is for	Premenopausal women with acquired, generalized HSDD; not indicated after menopause, in men, or for performance enhancement	No FDA-approved indication; marketed by Inner Balance across pre-, peri-, post-, and surgical menopause
Trials on this exact product	Two Phase 3 placebo-controlled trials; 1,247 women	None located; Inner Balance cites internal experience in more than 10,000 women without a public full protocol or report
Nausea	40% across trials; 21% after the first dose and about 3% after subsequent doses; 13% received anti-nausea medication	Provider calls nausea mild and often limited to the first dose; no Libida-specific incidence rate published
Heart and blood pressure	Contraindicated with uncontrolled hypertension or known cardiovascular disease	Product page excludes uncontrolled blood pressure and “untreated” heart disease; formulation-specific cardiovascular data are not public
Skin darkening	Focal hyperpigmentation about 1% at labeled use; higher risk in people with darker skin; may not resolve	Product page says about 1%, links it to exceeding the recommended dose, and says it often fades; no product-specific rate or persistence data published
Drug interactions	Delays gastric emptying; oral naltrexone should be avoided; timing of some oral drugs can matter	Some Inner Balance educational pages discuss naltrexone and oral-drug absorption, but the public product page does not present a complete interaction section
Current access price	Most eligible commercially insured patients may pay $0; $99 for a four-dose box without coverage through the manufacturer pathway	$249/10 once; $199/10 monthly; $249 or $279/20 every two months; $299/30 every three months
Insurance	Commercial coverage may be available; manufacturer terms apply	Inner Balance operates cash-pay and does not bill insurance
Refunds	Pharmacy, prescription, and program terms apply	Inner Balance’s published policy excludes Libida from refunds
Pharmacy transparency	Named manufacturer, FDA label, and defined specialty-pharmacy access pathway	Inner Balance says a certified U.S. pharmacy; public Libida page does not name the legal dispensing pharmacy

These are two different prescription products with different formulations, routes, evidence, contraindications, and approval status. A shared ingredient name, a similar timing window, or a similar price does not make them medically equivalent.

One thing we will not do: divide 1 mg by 1.75 mg and call one “stronger.” Those amounts enter the body by different routes, and no public study tells us how much of Libida’s sublingual dose reaches systemic circulation. A potency ratio would be invented certainty.

The three differences that decide this page

One finished product has been reviewed by the FDA. One has not.
One has controlled trials on the exact product and route you would use. One does not.
The cheaper-looking product is not always cheaper once billing cadence, unused tablets, insurance, and refunds are included.

How much does Vyleesi actually cost without insurance?

Cosette currently publishes a $99 four-dose Vyleesi box when insurance coverage is absent or denied through its BlinkRx pathway. That is $24.75 per dose. Most eligible commercially insured patients may pay $0, but eligibility and program terms control; ordinary retail or coupon listings can still exceed $1,000 for the same four-dose carton.

We want to be blunt about why this section exists.

Many comparison pages quote a retail or list-price figure around hundreds of dollars per injection, then place it beside Libida’s lowest unit cost and let you draw the obvious conclusion. The current manufacturer access pathway changes that comparison.

The four ways the price can appear

Access path	Published amount	Per dose	What the number means
Eligible commercial coverage plus Cosette assistance	As little as $0 per four-dose box	As little as $0	Not guaranteed; insurance approval and program eligibility apply
Cosette/BlinkRx cash pathway when coverage is absent or denied	$99 per four-dose box	$24.75	Current official manufacturer pathway; terms can change
Current GoodRx coupon listing checked August 2026	$1,284.44 per four-dose carton	$321.11	Retail/coupon benchmark, not the manufacturer’s direct access price
Telehealth or clinician access	Visit cost plus medication	Varies	A separate consult fee may apply if you do not already have a prescriber

That is a spread of more than ten to one on the same FDA-approved product. The lowest published path is on the manufacturer’s own site.

The fine print, because it matters

Cosette’s current terms say:

The $0 commercial-insurance pathway is for eligible patients; coverage and benefit design still matter.
Assistance is limited to two fills in 30 days.
Government-funded plans, including Medicaid and TRICARE, are not eligible for the copay assistance program.
Enrollment cannot be applied retroactively. Complete it before the fill.
Patients must be 18 or older.
The program may change or end.

The $99 pathway is not the same as the commercial-insurance copay program. Confirm the amount with BlinkRx before the prescription is filled.

→ See Cosette’s current Vyleesi pricing and eligibility terms
We earn nothing from this link. It goes to the manufacturer. Check the current terms before relying on any price stated here.

How much does Libida cost per tablet?

Inner Balance publishes four Libida purchase structures. The clear options calculate to $24.90, $19.90, and $9.97 per tablet. The 20-tablet option is contradictory: one official line says $249 while the same or related official copy also says $279 will be charged, producing either $12.45 or $13.95 per tablet. Verify the checkout amount.

Plan	Amount charged	Tablets	Billing cadence	Cost per tablet — our math	Verification status
One-time	$249	10	Once	$24.90	Published
Monthly subscription	$199	10	Monthly	$19.90	Published
Two-month subscription	$249 or $279	20	Every two months	$12.45 or $13.95	Official pages conflict; confirm checkout
Three-month subscription	$299	30	Every three months	$9.97	Published

Two things to notice.

The advertised $99.70 is the largest upfront commitment, not the amount necessarily charged today. The arithmetic is:

$299 ÷ 3 = $99.67, displayed as $99.70 per month.

The clean disclosure is $299 charged every three months for 30 tablets, equivalent to $99.67 per month. A monthly equivalent and an amount due today are not the same number.

The “$8–$10 per experience” line works only near the largest plan’s unit cost and only if “experience” means one tablet and every tablet is eventually used. The provider does not consistently define the unit. Cost per tablet is auditable. “Experience” is not.

The second problem with the largest plan is the one that actually hurts: the lowest price per tablet requires the largest non-refundable payment upfront. If you buy 30 tablets, use 12, and stop, your payment divided by the tablets actually used is $24.92 per used tablet. Eighteen tablets remain, and the published refund policy does not return the money.

The refill-accumulation problem

The Phase 3 Vyleesi trials do not tell us how often a Libida patient will use Libida. They do give a reasonable planning scenario for an on-demand bremelanotide product: many trial participants used two or three doses per month. That is not a prediction about your use.

At two or three uses a month, here is what the automatic billing cycle can look like before the next shipment:

Libida plan	Charge in the cycle	Uses before renewal at 2/month	Spend divided by those uses	Tablets left	Uses before renewal at 3/month	Spend divided by those uses	Tablets left
$199 monthly / 10 tablets	$199	2	$99.50	8	3	$66.33	7
$249 every 2 months / 20 tablets	$249	4	$62.25	16	6	$41.50	14
$279 every 2 months / 20 tablets	$279	4	$69.75	16	6	$46.50	14
$299 every 3 months / 30 tablets	$299	6	$49.83	24	9	$33.22	21

That is cash spent divided by uses before the next automatic renewal. It does not change the nominal $9.97–$24.90 tablet price if you cancel and eventually use every tablet. It shows the accumulation risk: a new shipment can arrive while most of the old one is still sitting there.

→ See the full Libida cost investigation — every published charge, the $249/$279 conflict, the no-refund rule, and the HSA/FSA contradiction.

Libida vs Vyleesi cost: which one is actually cheaper?

At the smallest posted Libida commitment, Vyleesi’s $99 cash pathway is slightly cheaper per dose: $24.75 versus $24.90. Libida becomes cheaper per tablet on its larger plans if every tablet is used. If you qualify for Vyleesi at $0, price stops being a contest. The remaining decision is medical fit and route.

Expected uses per month	Eligible Vyleesi at $0	Vyleesi cash at $24.75/dose	Libida one-time at $24.90/tablet	Libida 30-tablet plan at $9.97/tablet*
2	$0	$49.50	$49.80	$19.94
4	$0	$99.00	$99.60	$39.88
8	$0	$198.00	$199.20	$79.76

\*The Libida 30-tablet column allocates the $299 payment across all 30 tablets as though every tablet is eventually used. It is not a monthly bill. You pay $299 upfront, the product is excluded from refunds, and the pack would last about 15, 7.5, or 3.75 months at those use rates if you stopped automatic refills.

Vyleesi’s label says more than eight doses per month is not recommended. Libida’s public product page says no more than one tablet in 72 hours.

If you qualify for the $0 Vyleesi pathway, nothing in this table beats $0. If you do not, the honest picture is this: at low use, the two lowest-commitment cash options are within pennies. At higher use, Libida’s largest plan is cheaper per tablet—but only after a $299 non-refundable payment and only if those tablets are used.

Unused tablets are not a theoretical footnote. They are the hidden cost.

→ Calculate my real cost per dose
Separate the charge due now from the monthly equivalent, see how long each pack lasts at your expected use rate, and expose unused-tablet risk before you pay. No email. No health questions.

What would each option cost at your real use rate?

The sticker price does not tell you what either option will cost at your actual use rate. This calculator worksheet separates the charge due now, nominal cost per dose, spend before the next refill, pack duration, unused tablets, and annualized exposure. It calculates cost only—not medical fit or expected effectiveness.

Bremelanotide Cost-Per-Dose Comparator

Use this worksheet before you choose a plan. It does not assess medical fit.

Write down how many doses you realistically expect to use each month.
Multiply that number by $24.75 for the current Vyleesi cash pathway, subject to eligibility and program terms.
For Libida, write down the actual charge due now, not the monthly equivalent.
Multiply expected monthly uses by the number of months before renewal.
Divide the charge by expected uses before renewal.
Subtract expected uses from tablets shipped to see how many may remain when the next charge hits.

Formulas:

Expected uses before renewal = expected monthly uses × months in billing cycle
Spend per use before renewal = charge ÷ expected uses before renewal
Unused tablets at renewal = tablets shipped − expected uses before renewal
Nominal cost per tablet = charge ÷ tablets shipped

The nominal tablet price tells you what the pack costs if every tablet gets used. The spend-per-use-before-renewal figure tells you what the subscription does to your cash flow.

Why does Inner Balance quote different Vyleesi prices across its own pages?

Inner Balance’s current and recently indexed educational pages have used multiple Vyleesi or injectable-bremelanotide benchmarks—from $25–$130 to $250+ and $290 per injection—while the current manufacturer pathway publishes $99 for four doses. Those figures are not interchangeable: some appear to be retail estimates, some compounded-package estimates, and some are not clearly sourced.

We are going to lay this out plainly and let you draw your own conclusion.

Inner Balance page or article	Figure used for Vyleesi or injectable bremelanotide	Libida figure on or around that comparison	What the current manufacturer page says
PT-141 injection alternatives	$250+ per injection	$8–$25 per use	$99 per four-dose box without coverage
Female libido treatment cost guide	$290 per injection without insurance	About $10 per use	$24.75 per dose through the $99 pathway
Low sex drive medication guide	$50–$70 per dose in multi-dose packages	About $20–$25 per experience	$24.75 per dose through the $99 pathway
PT-141 for women guide	$25–$130+ per dose	$8–$10 per experience	$24.75 per dose through the $99 pathway

The prices may describe different purchase channels, but the pages do not consistently label those channels. That makes the comparison look cleaner than it is.

The $290 figure is almost twelve times the current $24.75 manufacturer-pathway unit price. Retail cash can still be high—the current GoodRx carton listing proves that—but a retail benchmark should not be presented as the only available cash route when the manufacturer publishes another one.

Here is a skill worth keeping: before trusting a seller’s comparison with Product B, look up Product B on its manufacturer’s site. It takes about a minute. It is the fastest way to tell whether you are reading a current acquisition comparison or a marketing benchmark.

Is Vyleesi approved for menopausal women?

No. Vyleesi’s current FDA label says it is not indicated for HSDD in postmenopausal women. Since December 2025, however, Addyi has been FDA-approved for acquired, generalized HSDD in women younger than 65, which includes qualifying postmenopausal women. That change makes “Libida versus Vyleesi” the wrong comparison for many readers after menopause.

This is where a lot of women find out they have been researching the wrong two products.

HSDD—hypoactive sexual desire disorder—is more specific than “my libido is lower than I want.” In these labels, low desire causes marked distress or interpersonal difficulty and is not better explained by a medical or psychiatric condition, relationship problem, medication, or another drug. “Acquired” means it developed after a previously satisfactory level of desire. “Generalized” means it occurs across situations, stimulation, and partners.

That exclusion matters. If your desire dropped after an antidepressant, when thyroid disease appeared, because sex became painful, during a severe depressive episode, or in an unsafe relationship, the next step is not automatically a desire drug.

Where you are changes the answer completely

Your stage	FDA-approved HSDD options relevant to the label	What is actually on the table
Premenopausal	Vyleesi and Addyi	Vyleesi is the only FDA-approved on-demand option; Addyi is daily
Perimenopausal	Depends on whether you are still premenopausal under the Vyleesi label; Addyi is indicated for women under 65	Menopause status is not a birthday. Ask the prescriber to document which label population you fit
Postmenopausal, under 65	Addyi	Daily 100 mg at bedtime; boxed warning and interaction rules apply; reassess at eight weeks
Postmenopausal, 65 or older	No FDA-approved HSDD drug under the current Vyleesi or Addyi labels	A broader evaluation; testosterone may be discussed off-label under specialist guidance

The December 2025 change most pages still miss

The current Addyi label is no longer limited to premenopausal women. It is indicated for women younger than 65 with acquired, generalized HSDD. The postmenopausal efficacy study included 447 women assigned Addyi and 455 assigned placebo; mean age was 55.

Addyi is a daily 100 mg bedtime pill, not an on-demand medicine. Its boxed warning covers severe hypotension and syncope in certain circumstances. The label requires alcohol-timing rules, contraindicates moderate or strong CYP3A4 inhibitors and hepatic impairment, and says to stop after eight weeks if there is no improvement.

That does not make Addyi the automatic winner. It makes it a real FDA-approved branch of the decision that older comparisons omit.

Where testosterone fits

For postmenopausal women with diagnosed HSDD, the 2019 Global Consensus Position Statement on testosterone therapy for women says the only evidence-based indication for testosterone therapy in women is postmenopausal HSDD after formal biopsychosocial assessment.

Four facts have to travel with that sentence every time:

There is no FDA-approved testosterone product for women in the United States. Prescribing is off-label.
Testosterone is a Schedule III controlled substance. It requires a prescription and clinician supervision.
The consensus recommendations do not apply to pellets, injections, compounded preparations, or any formulation that produces supraphysiologic testosterone concentrations. Physiologic female-range dosing and monitoring matter.
It is background therapy, not an on-demand medicine used before intimacy.

So let us say the uncomfortable thing

If you are past menopause, the comparison you came here for may be the wrong comparison.

Vyleesi’s approved label excludes postmenopausal women. Libida is not FDA-approved for any population. An FDA-approved daily option now exists for qualifying women under 65, and off-label transdermal testosterone has a separate evidence-based role after a proper assessment.

We would rather lose you at this paragraph than have you spend $299 because an ad made two products look like the only choices.

Does that sound like your situation? A clinician who works in menopause care can evaluate whether Addyi, off-label testosterone, local treatment for pain or dryness, medication adjustment, or another path fits.
→ Check whether Midi Health is in network with your plan and available in your state
Midi says it is available in all 50 states and in-network with most PPO plans; coverage varies. It is not enrolled with Medicaid or Medi-Cal and cannot treat those patients even as self-pay. Medicare beneficiaries may use Midi as self-pay but cannot submit claims. We have not confirmed which specific HSDD medicines Midi prescribes. This is access to an evaluation, not a prescription guarantee. Affiliate link; we may earn a commission.

Which one has stronger evidence?

Vyleesi has the stronger product-specific evidence. Its two Phase 3 trials in 1,247 premenopausal women showed statistically significant improvements in desire and distress about low desire, but not a statistically significant increase in satisfying sexual events. We found no published controlled trial of Libida’s exact tablet, strength, route, and ingredient combination.

Evidence comes in layers. The layers are not interchangeable.

Evidence layer	What it can honestly support	What it cannot support
Vyleesi’s FDA label and Phase 3 trials	Conclusions about the 1.75 mg injection in premenopausal women with acquired, generalized HSDD	A Libida effectiveness or safety rate
General bremelanotide pharmacology	Ingredient-level mechanism and known concerns worth asking about	That a sublingual combination behaves like an injection
Oxytocin studies	Whether broad oxytocin sexual-function claims have direct human support	An estimate of Libida’s combined effect
Inner Balance’s internal data	What the company reports about its users	An independently validated response rate
Provider-selected testimonials	One reported experience	Typicality, causation, safety, or efficacy

What the Vyleesi trials actually found

The two RECONNECT studies were 24-week, randomized, double-blind, placebo-controlled trials in 1,247 premenopausal women with acquired, generalized HSDD. The active group showed statistically significant improvements in the co-primary measures of sexual desire and distress related to low desire.

Those are real findings. They are why the product was approved.

They were not a promise of a dramatic transformation for every woman. Trial averages were modest, and placebo response was substantial. The label gives you the result, the denominator, and the adverse events—which is what an FDA-reviewed evidence record is supposed to do.

The result neither company puts in the spotlight

The trials also tracked satisfying sexual events. They did not show a statistically significant treatment difference on that endpoint; the reported p-values were 0.76 and 0.70.

That finding deserves space because it is the outcome most likely to sound like the real-life payoff.

Inner Balance’s Libida page plots “satisfying events per month” in its internal-result graphics and several of its educational pages describe bremelanotide as increasing satisfying sexual events. Cosette’s consumer marketing leads with desire and distress and does not foreground the null satisfying-event result either.

Both sellers select the evidence that tells the cleanest story. We checked both. The trials support increased desire and reduced distress. They did not establish more satisfying sexual events than placebo.

That is not “Vyleesi did nothing.” It is the exact boundary of what the trials showed.

What is public for Libida

Inner Balance says more than 10,000 women have tried Libida and reports improvements in desire, arousal, relaxation, openness, and satisfaction. It says more than half felt more mentally interested in intimacy within 60 minutes.

We could not locate a public protocol, randomization method, comparator, enrollment criteria, menopausal-status breakdown, exact analysis population, attrition table, complete adverse-event table, statistical analysis plan, or peer-reviewed paper for the exact finished product.

That does not prove the internal information is false. It means an outside reader cannot calculate how many women responded, how many did not, who stopped, what dose each received, or how the comparison was made.

The difference is not “one works and one does not.” The difference is one finished product has a public controlled evidence record that outsiders can inspect.

Does the oxytocin in Libida make it work better?

No published evidence establishes that it does. The most relevant randomized trial of oxytocin for sexual function in women found no significant advantage over placebo, and placebo numerically improved more on the primary sexual-function measure. That study used intranasal oxytocin alone in 30 women, so it cannot settle Libida’s sublingual combination either way.

Oxytocin is Libida’s differentiator. Inner Balance calls it the bonding hormone and positions the combination as addressing emotional connection alongside desire. It is an appealing story. Here is what has actually been tested.

Muin and colleagues published a randomized, double-blind, placebo-controlled crossover trial in Fertility and Sterility in 2015. Thirty pre- and postmenopausal women with sexual dysfunction used 32 IU intranasal oxytocin or placebo before intercourse. The timing resembles Libida’s as-needed concept; the route, formulation, and absence of bremelanotide do not.

Outcome	Oxytocin period	Placebo period
Female Sexual Function Index	+26%	+31%
Sexual quality of life	+144%	+125%
Sexual interest and desire	+29%	+23%
Sexual distress, where a decrease is better	−36%	−45%

The investigators found no significant treatment, sequence, or interaction effect separating oxytocin from placebo.

Two other human studies do not create a clean efficacy case. A laboratory crossover study found no significant effect on subjective or objective sexual parameters. A couples study reported some partner-interaction findings but not a consistent change in classic drive or arousal measures.

Now the limits, because they are real: these studies used intranasal oxytocin, not sublingual oxytocin; they tested oxytocin without bremelanotide; the largest relevant trial was small; and none studied Inner Balance’s finished tablet.

None of this proves Libida does not work. It does mean the “bonding pathway” story has not been shown to add a product-specific clinical benefit in a published trial.

One labeling detail matters. Libida is often marketed as non-hormonal because it contains no estrogen, progesterone, or testosterone. Oxytocin is a hormone. “No sex hormones” is defensible. “No hormone in it” is not.

Which works faster, and which lasts longer?

Vyleesi’s label says to inject at least 45 minutes before anticipated activity and states that the duration of efficacy after each dose is unknown. Inner Balance says Libida is taken 30–60 minutes before intimacy, but its duration language ranges from 4–12 hours for most women to 24–72 hours or “up to 72 hours,” without public tablet pharmacokinetic data.

This is where the marketing gets ahead of the evidence.

Onset: Vyleesi’s label gives an administration window—at least 45 minutes before—not a guarantee of when a person will feel a change. Inner Balance’s product page says 30–60 minutes; related articles often say 45–60 minutes. Those are provider instructions and claims, not a measured head-to-head result.

Duration: Vyleesi’s FDA label is blunt: the duration of efficacy after each dose is unknown, and the optimal administration window has not been fully characterized. Its terminal half-life is about 2.7 hours, which is not the same thing as duration of benefit.

Inner Balance’s public language is less consistent. The product page says effects can last up to 72 hours. A duration guide says 4–12 hours for most women, with some reporting 24–72 hours. Another comparison article says up to 24 hours.

There is no public pharmacokinetic study for the exact Libida tablet to tell us which duration statement belongs to which patient, dose, or outcome.

Why this matters to your wallet: the duration claim is what turns “cost per tablet” into “cost per experience.” If one tablet covers several distinct occasions, the seller’s per-experience math changes. If one tablet covers one occasion, it does not. The public evidence does not settle that conversion.

Which has more side effects?

Vyleesi has more published side-effect data, not necessarily more side effects. In its trials, 40% reported nausea, 13% received anti-nausea medication, and 18% discontinued because of adverse reactions. Libida publishes no product-specific incidence rate for any adverse event. A tablet avoids injection-site reactions, but no public study shows it avoids nausea, blood-pressure effects, or pigmentation.

There is a trap here.

Vyleesi’s numbers look bad. Libida’s marketing sounds gentler. But Libida does not publish comparable numbers. Comparing a measured risk with an unmeasured risk and declaring the unmeasured one lower is backwards.

Unknown does not mean lower. Hold on to that.

The nausea question, properly reconciled

Three nausea figures circulate, and they measure different things.

Figure	What it measures	Source
40% versus 1.3% on placebo	Women who reported nausea at any point in the controlled trials	FDA label
21% after first dose; about 3% after subsequent doses	Nausea associated with individual dosing occasions	FDA label and manufacturer patient materials
“Mild nausea… often only with first dose”	A qualitative marketing description without a Libida-specific rate	Inner Balance product page

The 40% counts anyone who had nausea during the trial. The dose-by-dose figure shows that nausea was concentrated early. Both statements can be true.

The label says median onset was within one hour and median duration was about two hours. Thirteen percent received an anti-emetic. A later study found that pretreatment with 8 mg ondansetron did not significantly reduce Vyleesi-associated nausea, so “just take an anti-nausea pill” should not be presented as a guaranteed fix.

Here is the part we would rather not tell you

Vyleesi’s nausea is not a footnote. Forty percent is a large measured rate. Eighteen percent discontinued because of adverse reactions, and nausea alone caused 8% to discontinue.

Libida’s needle-free format is still a genuine advantage. Some women will not inject themselves. An FDA-approved injector that stays in the box is not a useful treatment for that woman.

But the trade is not “nausea versus no nausea.” The trade is a measured, front-loaded risk attached to a defined product versus an unmeasured product-specific risk attached to a compounded tablet.

If needles are truly the dealbreaker, that is a legitimate reason to discuss Libida. Keep the financial risk visible: the lowest posted commitment is the one-time 10-tablet option at $249, and it has the highest tablet price. The $299 plan lowers the unit price but increases non-refundable exposure.

The other risks, side by side

Blood pressure and heart: Vyleesi temporarily raises blood pressure and lowers heart rate after each dose, generally resolving within 12 hours. It is contraindicated in uncontrolled hypertension or known cardiovascular disease. The label also says to consider overall cardiovascular risk before starting.

Inner Balance’s public product page says people with uncontrolled blood pressure or “untreated” heart disease should not use Libida. That wording is narrower than Vyleesi’s FDA contraindication. A different route and dose may change risk, but no public Libida study proves that treated cardiovascular disease becomes acceptable. Ask the prescriber directly.

Skin darkening: Vyleesi’s label reports focal hyperpigmentation in about 1% at labeled use, including the face, gums, and breasts. Risk was higher in people with darker skin, and resolution was not confirmed in every patient. Daily dosing in an earlier study produced much higher rates, which is one reason the use ceiling matters.

Inner Balance reports about 1% and says it often occurs when dosing exceeds its recommendation and often fades. Those statements appear to borrow context from bremelanotide data; Libida-specific incidence and persistence data are not public.

Other oral medicines: Vyleesi delays gastric emptying and may affect absorption of oral drugs. The label says to avoid oral naltrexone because exposure can be reduced enough to undermine treatment. Medicines that depend on threshold concentrations or rapid onset deserve review. Inner Balance discusses some of this in educational content, but not as a complete interaction section on the product page.

Pregnancy: Vyleesi should be stopped if pregnancy is suspected, and effective contraception is advised during treatment. Inner Balance says Libida should not be used during pregnancy. Neither product belongs in a “try it and see” decision when pregnancy is possible without a clinician reviewing the situation.

If Vyleesi already made you sick: that is a reason for clinician review, not proof Libida will sit better. A different route and formulation may behave differently, but Libida still contains bremelanotide according to Inner Balance and there are no public comparative nausea data.

Get urgent or in-person care instead of continuing an online purchase decision if

You have chest pain, fainting, a severe headache with neurological symptoms, trouble breathing, or another potentially urgent cardiovascular or neurological symptom.
You have new bleeding after menopause.
You may be pregnant and are considering or have used bremelanotide; contact the prescribing clinician promptly.
You are in a coercive or unsafe sexual situation, or you are in crisis.

Do not have a prescriber to discuss this with?
→ See current cash-pay visit prices before you book on Sesame
Sesame publishes upfront self-pay visit prices and does not accept insurance for provider visits. Availability, clinician scope, and prices vary. A prescription is never guaranteed. Affiliate link; we may earn a commission.

Is compounded bremelanotide legal?

A lawful compounding pathway can exist, but legality cannot be determined from a marketing page alone. Bremelanotide is a component of an FDA-approved drug, which can satisfy one ingredient condition under section 503A. The pharmacy, patient-specific prescription, sourcing, state law, and restrictions on drugs that are essentially copies still matter.

“Compounded” does not mean illegal. It also does not mean every compounded finished product automatically satisfies every federal and state condition.

Under section 503A, a licensed pharmacist or physician may qualify for compounding exemptions when the statutory conditions are met. FDA’s current bulk-substance page explains that a substance may be used when it complies with an applicable monograph, is a component of an FDA-approved drug, or qualifies through the 503A bulks pathway. Bremelanotide is the active ingredient in Vyleesi, so the component condition is relevant.

That answers one ingredient question. It does not answer the finished-product question.

Section 503A restricts regular or inordinate compounding of drugs that are essentially copies of commercially available products. FDA guidance says a prescriber’s determination that a change produces a significant difference for an identified patient can matter. The route, strength, dosage form, added oxytocin, and individual clinical rationale all belong in that analysis. Route difference alone is not a public legal ruling on Libida.

The clean questions are:

“Which legal pharmacy fills my prescription, and is it operating under section 503A or as a registered 503B outsourcing facility?”
“What patient-specific clinical reason is documented for this compounded sublingual combination rather than the approved injection?”
“What strength and complete ingredient list will appear on my prescription label?”

A good prescriber and pharmacy should be able to answer without turning it into a sales pitch.

→ Read the full Libida FDA-status and compounding analysis

Insurance, HSA/FSA, cancellation, and what happens if it does not work

Vyleesi may be covered by commercial insurance and has a manufacturer pathway that can reduce eligible patients’ cost to $0; a $99 four-dose cash option is also published. Inner Balance does not bill insurance. Libida is specifically excluded from its refund policy, and Inner Balance’s own pages conflict on whether Libida is HSA/FSA eligible.

Vyleesi and insurance

Coverage varies, and prior authorization may be required. The manufacturer pathway matters because it creates two routes: an eligible commercial-insurance path that may be $0 and a $99 four-dose path when coverage is absent or denied. Government-funded plans are excluded from the commercial copay assistance terms.

Do not wait until after the fill to enroll. The current terms say assistance is not retroactive.

Libida and insurance

Inner Balance’s terms say it does not accept or bill commercial insurance, Medicare, or Medicaid for its services. Treat Libida as cash-pay unless the company provides different current written terms.

The refund exclusion

Inner Balance’s refund policy names Libida directly among products to which refunds do not apply.

That matters because the money-back guarantee is part of the broader brand’s risk-reversal language. It does not protect this purchase.

“Cancel anytime” is not “refund anytime.” Cancellation may stop a future renewal. Inner Balance’s public terms do not clearly state the last cancellation moment relative to billing, clinician approval, pharmacy transmission, or preparation. Save the cancellation confirmation and ask whether a processed order can still be stopped.

The HSA/FSA contradiction

Libida’s product page and multiple Inner Balance articles display “HSA/FSA eligible.” Inner Balance’s dedicated HSA/FSA page says only Oestra is currently eligible.

We are not choosing the more convenient sentence. The company’s own sources conflict.

If pre-tax dollars are the reason the purchase feels affordable, do not pay until you have current written confirmation from Inner Balance and your plan administrator. A card transaction being accepted is not proof that an expense qualifies under your account rules.

→ How Inner Balance handles insurance, HSA/FSA, and refunds

What do reviews actually tell you here?

Not enough to calculate your odds. Inner Balance publishes selected Libida testimonials, and Cosette publishes selected statements from Vyleesi trial participants. We did not locate a large independent Libida-specific review pool with a verifiable denominator, product identity, dose, follow-up period, and outcome method. That is why this page gives neither product a star rating.

A review can tell you what one person says happened. It cannot tell you whether the product caused the result, how typical the result is, or whether the reviewer had the same diagnosis, menopause status, dose, medications, or risk history as you.

Company-level Inner Balance reviews are also a poor substitute because they mix Libida, Oestra, skincare, billing, shipping, and customer service. Product-specific evidence gets lost.

Cosette’s official Vyleesi site publishes this statement from a person identified as a clinical-trial participant:

“I've been having more sexual thoughts and more interest in initiating.”

The manufacturer selected and published that statement. It is one reported experience, not a typical result and not a substitute for the full trial data.

That is as much weight as a testimonial should carry.

A useful Libida review would state the exact dispensed strength, menopause status, whether the problem was desire rather than pain or dryness, number of attempts, other medication changes, adverse events, follow-up period, cancellation experience, and financial relationship with the seller. Most short reviews give you none of that.

Which one fits your situation?

There is no universal winner. For a premenopausal woman who fits the Vyleesi label and has no contraindication, Vyleesi is the stronger starting point and may cost $0. After menopause, neither product is the automatic answer. For someone who truly will not inject, Libida has a real route advantage—but it comes with weaker product-specific evidence and no refund.

Your situation	Where this evidence points	Why
Premenopausal, eligible commercial insurance	Ask about Vyleesi	FDA-approved for the population; may be $0 under current terms
Premenopausal, no coverage	Compare Vyleesi’s $99 four-dose path with Libida’s smallest commitment	$24.75 per Vyleesi dose versus $24.90 per Libida tablet at the one-time plan
Premenopausal, absolutely will not inject	Discuss Libida, with the smallest financial exposure first	Needle-free route is the honest use case; compounded status and no-refund rule remain
Perimenopausal, status unclear	Get the label population documented	Vyleesi eligibility turns on premenopausal status, not age alone
Postmenopausal, under 65	Ask whether Addyi or another menopause-specific path fits	Addyi now has an FDA-approved HSDD indication for women under 65
Postmenopausal, 65 or older	Full evaluation	Neither Vyleesi nor Addyi is indicated under the current labels; testosterone is off-label and Schedule III
Medicaid or TRICARE	Verify the $99 Vyleesi cash path directly	The commercial copay program excludes government-funded plans; do not assume eligibility
Known cardiovascular disease or uncontrolled blood pressure	Do not use Vyleesi; get clinician evaluation before any bremelanotide option	Vyleesi’s label makes these contraindications
Pain or dryness is the main issue	Start with the GSM and vaginal-estrogen path	A desire drug does not repair painful or fragile vaginal tissue
Desire changed after a new medicine	Return to the prescriber who wrote it	Medication effects must be considered before diagnosing HSDD
You need a refund if the product is not a fit	Not Libida	The published refund policy excludes it
You need a public dose, label, pharmacy pathway, and trial record	Vyleesi	Those records are public and product-specific

We did not route this page to whichever affiliate pays most. Winona is one of our partners, but it does not answer the Libida-versus-Vyleesi question and is compounded-primary. A page whose central argument is “know the finished product and dose” should not quietly change the subject to another compounder.

What should you check before you pay for Libida or Vyleesi?

Before paying, confirm the exact product, strength, charge due today, refill date, cancellation and refund treatment, pharmacy, state access, interaction risks, and what happens if the clinician declines to prescribe. Save the checkout screen and written answers. The irreversible facts should be clear before the card is charged.

If you are looking at Libida

What exact bremelanotide and oxytocin strengths will be on my dispensed label?
Which pharmacy fills it? What is the pharmacy’s legal name and state license?
Is the prescription compounded under a patient-specific 503A pathway or supplied through a 503B outsourcing facility?
What patient-specific clinical difference justifies this compounded route for me?
Is there product-specific absorption, stability, potency, or certificate-of-analysis information I can inspect?
Exactly how much is charged today—not the monthly equivalent—and how many tablets ship?
For the 20-tablet plan, is today’s charge $249 or $279?
What is the next renewal date, and what is the last date and time I can cancel?
Can an order be stopped after clinician approval or pharmacy processing?
What amount is returned if the clinician declines to prescribe?
Is Libida HSA/FSA eligible today? Can you provide that in writing?
Is it available in my state through the clinician and named pharmacy?
How will cardiovascular history and blood pressure be evaluated?
What is the plan for nausea, headache, flushing, blood-pressure symptoms, or pigmentation?
Do any of my oral medicines—including naltrexone—create a timing or absorption problem?
Who handles an adverse effect, through which channel, and within what response time?

If you are looking at Vyleesi

Do I meet the labeled premenopausal, acquired, generalized HSDD criteria?
Have medication effects, pain, dryness, thyroid disease, depression, relationship factors, trauma, and other causes been considered?
Is my blood pressure controlled?
Do I have known cardiovascular disease or a high cardiovascular risk that changes the answer?
Could I be pregnant, and what contraception guidance applies?
Do I take oral naltrexone or another oral medicine where delayed absorption matters?
Am I eligible for the commercial-insurance assistance, or does the $99 cash path apply?
Has enrollment been completed before the fill, since assistance is not retroactive?
What should I do if nausea is severe, and when should I stop?
How will skin pigmentation be monitored, especially if I have darker skin?
What is the reassessment point if desire or distress does not improve?
Which pharmacy will dispense the four-dose box, and what will I pay before it ships?

Print this section or save it with the final checkout screen. No email is required to use it.

Frequently asked questions about Libida vs Vyleesi

These answers close the questions most likely to send a reader back to search: approval, price, menopause status, nausea, duration, refunds, HSA/FSA use, controlled-substance status, and what to do when pain or dryness is the real problem. Each answer preserves the condition that changes the result.

Is Libida the same as Vyleesi?

No. Vyleesi is an FDA-approved 1.75 mg bremelanotide injection. Libida is a compounded sublingual product that Inner Balance says combines bremelanotide with oxytocin. The route, formulation, dose record, evidence, labeling, quality controls, and regulatory oversight differ. Ingredient overlap does not make the finished products equivalent.

Which is better, Libida or Vyleesi?

For a premenopausal woman who meets the Vyleesi indication and has no contraindication, Vyleesi is the stronger evidence-based starting point. Its dose, trial record, risks, and manufacturer pricing are public. Libida’s real advantage is needle-free use. After menopause, neither is the automatic answer; Addyi or another menopause-specific evaluation may fit better.

Is Libida FDA-approved?

No. Libida is compounded, and the finished product is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing in the way it reviews approved drugs. Compounding can be lawful; lawful and FDA-approved are different claims.

Is Vyleesi really $290 per injection?

That can describe a retail-style benchmark, but it is not the complete current access picture. Cosette publishes a $99 four-dose pathway—$24.75 per dose—when coverage is absent or denied, and says most eligible commercially insured patients may pay $0. Program terms apply. Retail or coupon prices can still exceed $1,000 per carton.

How much does Vyleesi cost without insurance?

The current official manufacturer pathway publishes $99 for a four-dose box when coverage is absent or denied, equal to $24.75 per dose. Confirm eligibility and the final amount with BlinkRx before the prescription is filled. Retail pricing outside that pathway can be far higher.

Does Libida contain the same active ingredient as Vyleesi?

Inner Balance says Libida contains bremelanotide, which is the active ingredient in Vyleesi, and adds oxytocin. We do not describe the products as having the “same active ingredient” in a way that implies sameness: the strength, route, formulation, absorption, evidence, and regulatory status differ.

Does Vyleesi increase satisfying sexual events?

The pivotal trials did not show a statistically significant treatment difference from placebo on satisfying sexual events; the reported p-values were 0.76 and 0.70. They did show statistically significant improvements in sexual desire and distress related to low desire. Approval should not be read as proof of more satisfying encounters.

Does the oxytocin in Libida make it work better?

It has not been established in a published trial of the finished product. A small randomized intranasal oxytocin trial in women found no significant advantage over placebo, but it did not test Libida’s route or bremelanotide combination. The evidence neither proves nor quantifies an added Libida benefit.

Which causes more nausea?

Vyleesi has a published rate: 40% across the controlled trials, with nausea concentrated after the first dose. Libida has no public product-specific incidence rate. That prevents a numerical comparison. Unknown is not the same as lower.

Can I try Libida if Vyleesi made me sick?

Only after clinician review. A different route and formulation may produce a different exposure, but Libida still contains bremelanotide according to Inner Balance, and no published comparison proves it avoids nausea. Bring the timing, severity, blood-pressure symptoms, other medicines, and treatment required for the Vyleesi reaction.

Can postmenopausal women use Vyleesi?

Vyleesi’s FDA label says it is not indicated for HSDD in postmenopausal women. That does not make Libida the automatic alternative. Addyi is now FDA-approved for acquired, generalized HSDD in women younger than 65, including qualifying postmenopausal women.

Is Libida better after menopause?

There is no published controlled evidence establishing that. Inner Balance markets Libida to postmenopausal women, but “marketed for” is not “FDA-approved for” or “shown in a controlled trial of this product.” The cause of the desire change and the full postmenopausal treatment set should be evaluated first.

Which is better if I hate needles?

Libida wins on route: it is a tablet and avoids injection-site reactions. Needle aversion is real. The trade is less product-specific transparency and evidence, an unnamed public pharmacy pathway, conflicting commercial terms, and no refund. That trade should be explicit, not hidden behind “needle-free.”

How long does each one last?

Vyleesi’s label says duration of efficacy after each dose is unknown. Inner Balance’s Libida claims range from 4–12 hours for most women to 24–72 hours or up to 72 hours. No public pharmacokinetic study of the exact tablet was located, so the longest claim remains provider-stated.

Can I get a refund on Libida?

Inner Balance’s published refund policy specifically excludes Libida. “Cancel anytime” may stop a future renewal; it does not promise that a processed charge or prepared prescription will be refunded. Ask for the cancellation cutoff before selecting a subscription.

Can I use HSA or FSA funds for Libida?

Inner Balance’s public pages conflict. The Libida sales and educational pages say it is HSA/FSA eligible, while the dedicated HSA/FSA page says only Oestra is currently eligible. Get written confirmation from Inner Balance and your account administrator before paying. Card acceptance alone does not prove tax eligibility.

Is either one a controlled substance?

Neither bremelanotide nor oxytocin appears on the current federal controlled-substance schedules reviewed in August 2026. Both products still require a prescription and clinician oversight. Testosterone, which may enter the postmenopausal HSDD discussion, is a Schedule III controlled substance under federal law.

What if pain or dryness is the real problem?

Then a desire drug may be the wrong next step. Genitourinary syndrome of menopause can make intimacy painful, and avoiding pain can look like low desire. Local vaginal therapies, lubricants, moisturizers, pelvic-floor care, and an examination for other causes belong in that pathway. Start with vaginal estrogen and GSM.

Is there a pill version of Vyleesi?

No FDA-approved oral or sublingual Vyleesi exists. Vyleesi is approved as a subcutaneous autoinjector. Compounded sublingual bremelanotide products are different finished products and should not be called approved oral Vyleesi.

The bottom line

Both products are described as containing bremelanotide. Only one finished product has been reviewed by the FDA, and that approval is limited to premenopausal women with acquired, generalized HSDD.

If you are premenopausal and fit the label, the FDA-approved option is not automatically the expensive one. Cosette currently publishes as little as $0 for eligible commercially insured patients and $99 for four doses when coverage is absent or denied. Check the terms before the fill.

If you are past menopause, the honest answer is that this may be the wrong comparison. Vyleesi excludes postmenopausal women under its label. Libida has no FDA-approved indication. Since December 2025, Addyi has an approved HSDD indication for women under 65, and off-label testosterone has a separate evidence-based role after a formal assessment.

Libida’s strongest honest case is not that it is “the same medicine without the needle.” It is that some women will not use an injection, and a clinician may decide a compounded sublingual combination offers a patient-specific route worth considering.

Its liabilities are just as real: no published controlled trial of the finished product, no public tablet pharmacokinetics, no named pharmacy on the product page, conflicting price and HSA language, and no refund.

You do not need permission to want your desire back. You do deserve to know which product was tested, what you will be charged today, what risk is measured, what remains unknown, and what happens if it is not a fit.

Still not sure which HRT program is right for you? Take our free matching quiz — about 90 seconds.

→ Use Find My HRT Path

You will get a personalized starting point—and a flag when online care is not the right place to begin. Your answers are handled under our consumer health data privacy policy.

Sources

Medical and regulatory claims are traced to FDA materials, current prescribing information, and peer-reviewed research. Provider prices, policies, dosing instructions, and access claims are traced to dated manufacturer or provider pages, with conflicts left visible instead of silently resolved.

FDA, labels, and federal guidance

Manufacturer and provider sources

Peer-reviewed evidence

Found a changed price, revised label, new study, or policy update? Send the source through our corrections page. We recheck material claims and publish the verification date.

Keep comparing the evidence and route

Read the Libida review, compare Libida with Addyi, review Vyleesi access and cost, or use the free Find My HRT Path tool.

Keep reading: